- CEO
- Cheung Tai Choi
- Full Time Employees
- 1,468
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Two Harbourfront Hong Kong Hong Kong
- IPO Date
- Jul 13, 2016
- Business
- Vincent Medical Holdings Limited, an investment holding company incorporated in the Cayman Islands in 1997 and headquartered at Units 1604-07A, 16th Floor, Two Harbourfront, 22 Tak Fung Street, Hung Hom, Kowloon, Hong Kong, researches, develops, manufactures, markets, trades in, and sells medical devices with production facilities in Dongguan, China, and R&D centers in Dongguan Songshan Lake Technology Industrial Park; the company operates through two segments, Original Equipment Manufacturing (OEM) and Original Brand Manufacturing (OBM), serving markets including the United States, Spain, Japan, the People's Republic of China, Costa Rica, the Netherlands, Australia, Germany, Sweden, Israel, and internationally.
The company's core products encompass respiratory care devices such as high-flow oxygen therapy systems, respiratory humidification systems, nCPAP interface systems, respiratory care units, electronic air-oxygen blenders, anesthesia systems, and related disposables; imaging disposables including contrast media power injector syringes, tubing, and accessories; orthopedic and rehabilitation products comprising adjustable braces for skeletomuscular support and protection post-injury or surgery, rehab-robotics solutions, and robotic hand training devices under brands like Hand of Hope; as well as other healthcare and wellness products including surgical patient warming systems; products are marketed under Inspired Medical, inspired, and Hypnus brands.
Vincent Medical Holdings Limited, a subsidiary of Vincent Raya International Limited, employs 1,328 staff and focuses on OEM partnerships with leading diagnostic imaging providers while expanding OBM offerings; in 2024, revenue grew 11.6% to HK$801.0 million, driven by a 37.7% surge in imaging disposables to HK$393.3 million, offsetting declines in respiratory (down 10.7% to HK$245.5 million) and orthopedic segments; the company achieved EU MDR certification for respiratory devices, passed FDA inspection with "No Action Indicated," launched an upgraded ERP system, entered a strategic smart manufacturing agreement with Siemens Digital Industries Software in April 2024, topped out Phase 1 of its new production facility in Kaiping City (trial operations by end-2025), and opened a Taobao store; for the six months ended June 30, 2025, revenue rose 18.1% to HK$449.4 million with profit up 55.1% to HK$51.6 million, declaring an interim dividend of HK2.4 cents per share.